JP2020509776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509776A5 JP2020509776A5 JP2019551272A JP2019551272A JP2020509776A5 JP 2020509776 A5 JP2020509776 A5 JP 2020509776A5 JP 2019551272 A JP2019551272 A JP 2019551272A JP 2019551272 A JP2019551272 A JP 2019551272A JP 2020509776 A5 JP2020509776 A5 JP 2020509776A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- polypeptide
- domain
- cell
- immunomodulatory protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 109
- 102000004169 proteins and genes Human genes 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 230000002519 immonomodulatory effect Effects 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 46
- 102220385089 c.128A>G Human genes 0.000 claims description 42
- 102220088392 rs5030804 Human genes 0.000 claims description 37
- 102200115851 rs79977247 Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 102220484783 Norrin_S75P_mutation Human genes 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 102220480183 Alkaline phosphatase, germ cell type_V58A_mutation Human genes 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 230000009870 specific binding Effects 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 21
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 102200015515 rs797045155 Human genes 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102220005273 rs33915112 Human genes 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 102220024919 rs199472829 Human genes 0.000 claims description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 230000001086 cytosolic effect Effects 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000004957 immunoregulator effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 102220363288 c.167T>A Human genes 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 102000048362 human PDCD1 Human genes 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 102220588802 Acidic mammalian chitinase_N45D_mutation Human genes 0.000 claims 68
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 37
- 102220238825 rs1554306353 Human genes 0.000 claims 32
- 102220348392 c.107T>C Human genes 0.000 claims 30
- 102220487169 Cytosolic Fe-S cluster assembly factor NUBP1_M97L_mutation Human genes 0.000 claims 24
- 102220036452 rs137882485 Human genes 0.000 claims 16
- 102220310594 rs1555523411 Human genes 0.000 claims 11
- 102220005507 rs33949106 Human genes 0.000 claims 6
- 102220353740 c.266A>G Human genes 0.000 claims 5
- 102220286853 rs1554309012 Human genes 0.000 claims 5
- 102220012912 rs397516363 Human genes 0.000 claims 5
- 102220045806 rs587782402 Human genes 0.000 claims 5
- 102220346271 c.69A>C Human genes 0.000 claims 4
- 101100218695 Bacillus subtilis (strain 168) bglH gene Proteins 0.000 claims 3
- 102220475222 Vacuolar protein sorting-associated protein 33A_R64S_mutation Human genes 0.000 claims 3
- 102220204092 rs1057522674 Human genes 0.000 claims 3
- 102200074788 rs111033567 Human genes 0.000 claims 3
- 102220001770 rs137852957 Human genes 0.000 claims 3
- 102220065371 rs144334386 Human genes 0.000 claims 3
- 102220244685 rs1555802745 Human genes 0.000 claims 3
- 102200107383 rs199815268 Human genes 0.000 claims 3
- 102220246750 rs200952460 Human genes 0.000 claims 3
- 102220005479 rs34182019 Human genes 0.000 claims 3
- 102220046321 rs587782831 Human genes 0.000 claims 3
- 102220231488 rs60290646 Human genes 0.000 claims 3
- 102220215713 rs772873692 Human genes 0.000 claims 3
- 102220573377 Alpha-enolase_M97I_mutation Human genes 0.000 claims 2
- 102220592171 Alpha-lactalbumin_I98L_mutation Human genes 0.000 claims 2
- 102220584249 Cellular tumor antigen p53_A79T_mutation Human genes 0.000 claims 2
- 102220559986 Epsilon-sarcoglycan_H60R_mutation Human genes 0.000 claims 2
- 102220535340 Ferredoxin-2, mitochondrial_H51N_mutation Human genes 0.000 claims 2
- 102220569456 Fumarylacetoacetate hydrolase domain-containing protein 2A_F49S_mutation Human genes 0.000 claims 2
- 102220495859 Putative protein ZBED10P_Y10F_mutation Human genes 0.000 claims 2
- 102220493431 Putative uncharacterized protein encoded by MIR7-3HG_K28N_mutation Human genes 0.000 claims 2
- 102220568715 Vascular endothelial growth factor receptor 1_N45I_mutation Human genes 0.000 claims 2
- 102220348984 c.128A>T Human genes 0.000 claims 2
- 102220362001 c.164A>G Human genes 0.000 claims 2
- 102220363876 c.218A>G Human genes 0.000 claims 2
- 102220389202 c.83A>T Human genes 0.000 claims 2
- 102220224597 rs1060500909 Human genes 0.000 claims 2
- 102200012564 rs111033663 Human genes 0.000 claims 2
- 102220075324 rs146331571 Human genes 0.000 claims 2
- 102220138536 rs146905561 Human genes 0.000 claims 2
- 102220258284 rs1553640189 Human genes 0.000 claims 2
- 102220328191 rs1555592039 Human genes 0.000 claims 2
- 102220312388 rs1555603894 Human genes 0.000 claims 2
- 102220295832 rs1555831004 Human genes 0.000 claims 2
- 102220024629 rs267607615 Human genes 0.000 claims 2
- 102220024604 rs267607644 Human genes 0.000 claims 2
- 102200164346 rs267607727 Human genes 0.000 claims 2
- 102220005268 rs33912272 Human genes 0.000 claims 2
- 102220005475 rs33960522 Human genes 0.000 claims 2
- 102220005371 rs33967561 Human genes 0.000 claims 2
- 102200092863 rs34289459 Human genes 0.000 claims 2
- 102200089581 rs5030804 Human genes 0.000 claims 2
- 102200110418 rs570878629 Human genes 0.000 claims 2
- 102220045124 rs587781846 Human genes 0.000 claims 2
- 102220024649 rs60290646 Human genes 0.000 claims 2
- 102220058097 rs730881898 Human genes 0.000 claims 2
- 102220129326 rs765777463 Human genes 0.000 claims 2
- 102200037607 rs771019366 Human genes 0.000 claims 2
- 102220068569 rs794727519 Human genes 0.000 claims 2
- 102200114229 rs797045192 Human genes 0.000 claims 2
- 102200067145 rs80356929 Human genes 0.000 claims 2
- 102200067146 rs80357017 Human genes 0.000 claims 2
- 102220095972 rs876660949 Human genes 0.000 claims 2
- 102220101425 rs878853501 Human genes 0.000 claims 2
- 102220482187 tRNA pseudouridine synthase A_Y14S_mutation Human genes 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102220032362 rs104895227 Human genes 0.000 claims 1
- 102220103860 rs138178722 Human genes 0.000 claims 1
- 102200036669 rs200330818 Human genes 0.000 claims 1
- 102220056057 rs727505029 Human genes 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 13
- 102220483589 Nuclear cap-binding protein subunit 1_N45D_mutation Human genes 0.000 description 10
- 102220235927 rs774648934 Human genes 0.000 description 9
- 102200136076 rs146599962 Human genes 0.000 description 8
- 206010047115 Vasculitis Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 102000054189 human CD80 Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 102200086056 rs41494349 Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129840A JP2023057022A (ja) | 2017-03-16 | 2022-08-17 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2023038522A JP7701395B2 (ja) | 2017-03-16 | 2023-03-13 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2025104061A JP2025138715A (ja) | 2017-03-16 | 2025-06-19 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472554P | 2017-03-16 | 2017-03-16 | |
| US62/472,554 | 2017-03-16 | ||
| US201762475076P | 2017-03-22 | 2017-03-22 | |
| US62/475,076 | 2017-03-22 | ||
| US201762537923P | 2017-07-27 | 2017-07-27 | |
| US62/537,923 | 2017-07-27 | ||
| US201762582249P | 2017-11-06 | 2017-11-06 | |
| US62/582,249 | 2017-11-06 | ||
| PCT/US2018/022265 WO2018170021A1 (en) | 2017-03-16 | 2018-03-13 | Pd-l1 variant immunomodulatory proteins and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129840A Division JP2023057022A (ja) | 2017-03-16 | 2022-08-17 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2023038522A Division JP7701395B2 (ja) | 2017-03-16 | 2023-03-13 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509776A JP2020509776A (ja) | 2020-04-02 |
| JP2020509776A5 true JP2020509776A5 (https=) | 2021-04-22 |
| JP7664022B2 JP7664022B2 (ja) | 2025-04-17 |
Family
ID=61952964
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551272A Active JP7664022B2 (ja) | 2017-03-16 | 2018-03-13 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2022129840A Pending JP2023057022A (ja) | 2017-03-16 | 2022-08-17 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2023038522A Active JP7701395B2 (ja) | 2017-03-16 | 2023-03-13 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2025104061A Pending JP2025138715A (ja) | 2017-03-16 | 2025-06-19 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129840A Pending JP2023057022A (ja) | 2017-03-16 | 2022-08-17 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2023038522A Active JP7701395B2 (ja) | 2017-03-16 | 2023-03-13 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
| JP2025104061A Pending JP2025138715A (ja) | 2017-03-16 | 2025-06-19 | Ｐｄ－ｌ１バリアント免疫調節タンパク質及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20230220039A1 (https=) |
| EP (2) | EP3596116B1 (https=) |
| JP (4) | JP7664022B2 (https=) |
| KR (3) | KR20240123406A (https=) |
| CN (2) | CN110831963B (https=) |
| AU (2) | AU2018236224B2 (https=) |
| CA (1) | CA3053804C (https=) |
| DK (1) | DK3596116T5 (https=) |
| ES (1) | ES2963638T3 (https=) |
| FI (1) | FI3596116T3 (https=) |
| HR (1) | HRP20231382T1 (https=) |
| HU (1) | HUE064136T2 (https=) |
| IL (2) | IL320149A (https=) |
| LT (1) | LT3596116T (https=) |
| PL (1) | PL3596116T3 (https=) |
| PT (1) | PT3596116T (https=) |
| RS (1) | RS64870B1 (https=) |
| SI (1) | SI3596116T1 (https=) |
| SM (1) | SMT202300477T1 (https=) |
| WO (1) | WO2018170021A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3596116B1 (en) * | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| MX2020007357A (es) | 2017-09-26 | 2021-08-11 | Longwood Univ | Reporte de antígeno quimérico específico de pd1 como una inmunoterapia. |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| AU2019205273B2 (en) * | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CA3120868A1 (en) * | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| WO2021062184A1 (en) * | 2019-09-26 | 2021-04-01 | Orionis Biosciences, Inc. | Pd-l1 targeted chimeric proteins and uses thereof |
| WO2021155132A1 (en) * | 2020-01-29 | 2021-08-05 | University Of Washington | De novo stable, modular pd-1 binding proteins and oligomeric variants |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| WO2022170033A1 (en) * | 2021-02-04 | 2022-08-11 | The Trustees Of Dartmouth College | Engineered natural ligand-based car: directed evolution of the stress-receptor nkp30 |
| KR20240099460A (ko) * | 2021-11-11 | 2024-06-28 | 리제너론 파아마슈티컬스, 인크. | Cd20-pd1 결합 분자 및 이의 사용 방법 |
| JP2025504722A (ja) * | 2022-01-25 | 2025-02-18 | 上海邦耀生物科技有限公司 | 修飾細胞及びその使用 |
| WO2023172883A1 (en) * | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| WO2025257209A1 (en) * | 2024-06-10 | 2025-12-18 | Phialogics Ag | Human pdl1 polypeptide variants |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0584266B1 (en) | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| WO1996009380A1 (en) | 1994-09-23 | 1996-03-28 | The University Of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| EP1012236A1 (en) | 1997-08-15 | 2000-06-28 | Rubicon Laboratory Inc. | Retrovirus and viral vectors |
| EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| US6375952B1 (en) | 1998-08-07 | 2002-04-23 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| AU2584901A (en) | 1999-12-22 | 2001-07-03 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| HUP0400882A3 (en) | 2001-05-11 | 2011-01-28 | Wellstat Biologics Corp | Oncolytic virus therapy |
| CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| US20050220818A1 (en) | 2002-06-21 | 2005-10-06 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| AU2003268505A1 (en) | 2002-09-09 | 2004-03-29 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JP2007524363A (ja) | 2003-03-27 | 2007-08-30 | オタワ ヘルス リサーチ インスティチュート | 変異体水疱性口内炎ウイルスおよびそれらの使用 |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| ATE420160T1 (de) | 2003-06-18 | 2009-01-15 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| US20070003520A1 (en) | 2003-11-17 | 2007-01-04 | Brown Susanne M | Mutant viruses |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| AU2006262021C1 (en) | 2005-06-23 | 2012-05-10 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| US8329162B2 (en) | 2006-07-21 | 2012-12-11 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| US20100178684A1 (en) | 2006-12-21 | 2010-07-15 | Woo Savio L C | Transgenic oncolytic viruses and uses thereof |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| GB2446721B (en) | 2007-02-16 | 2009-03-25 | Crusade Lab Ltd | Herpes simplex viruses and methods of viral replication |
| CA2690627C (en) | 2007-06-15 | 2014-12-02 | Genelux Corporation | Microorganisms for imaging and/or treatment of tumors |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| JP2010533718A (ja) | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| EP2225277A4 (en) | 2007-11-27 | 2012-03-14 | Viventia Biotech Inc | ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| US20120052003A9 (en) | 2008-05-16 | 2012-03-01 | Szalay Aladar A | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| RS53257B2 (sr) | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| JP6355563B2 (ja) | 2012-02-27 | 2018-07-11 | アムニクス オペレーティング インコーポレイテッド | Ｘｔｅｎ共役組成物およびそれを製造する方法 |
| WO2013149167A1 (en) | 2012-03-30 | 2013-10-03 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| CN121159719A (zh) * | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| WO2017029389A1 (en) * | 2015-08-20 | 2017-02-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | B7-h1 fusion polypeptides for treating and preventing organ failure |
| WO2018022945A1 (en) * | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| WO2018022946A1 (en) * | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3596116B1 (en) * | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
-
2018
- 2018-03-13 EP EP18717149.1A patent/EP3596116B1/en active Active
- 2018-03-13 JP JP2019551272A patent/JP7664022B2/ja active Active
- 2018-03-13 US US16/493,752 patent/US20230220039A1/en not_active Abandoned
- 2018-03-13 EP EP23195083.3A patent/EP4306537A3/en active Pending
- 2018-03-13 IL IL320149A patent/IL320149A/en unknown
- 2018-03-13 IL IL268780A patent/IL268780B2/en unknown
- 2018-03-13 CA CA3053804A patent/CA3053804C/en active Active
- 2018-03-13 KR KR1020247026055A patent/KR20240123406A/ko active Pending
- 2018-03-13 PL PL18717149.1T patent/PL3596116T3/pl unknown
- 2018-03-13 CN CN201880031791.0A patent/CN110831963B/zh active Active
- 2018-03-13 RS RS20231112A patent/RS64870B1/sr unknown
- 2018-03-13 HU HUE18717149A patent/HUE064136T2/hu unknown
- 2018-03-13 SI SI201831015T patent/SI3596116T1/sl unknown
- 2018-03-13 PT PT187171491T patent/PT3596116T/pt unknown
- 2018-03-13 WO PCT/US2018/022265 patent/WO2018170021A1/en not_active Ceased
- 2018-03-13 AU AU2018236224A patent/AU2018236224B2/en active Active
- 2018-03-13 SM SM20230477T patent/SMT202300477T1/it unknown
- 2018-03-13 CN CN202411466279.2A patent/CN119161451A/zh active Pending
- 2018-03-13 FI FIEP18717149.1T patent/FI3596116T3/fi active
- 2018-03-13 KR KR1020197030430A patent/KR102692556B1/ko active Active
- 2018-03-13 LT LTEPPCT/US2018/022265T patent/LT3596116T/lt unknown
- 2018-03-13 KR KR1020247008722A patent/KR20240039221A/ko active Pending
- 2018-03-13 HR HRP20231382TT patent/HRP20231382T1/hr unknown
- 2018-03-13 ES ES18717149T patent/ES2963638T3/es active Active
- 2018-03-13 DK DK18717149.1T patent/DK3596116T5/da active
-
2022
- 2022-08-17 JP JP2022129840A patent/JP2023057022A/ja active Pending
-
2023
- 2023-03-13 JP JP2023038522A patent/JP7701395B2/ja active Active
-
2024
- 2024-03-26 AU AU2024201931A patent/AU2024201931A1/en active Pending
-
2025
- 2025-06-19 JP JP2025104061A patent/JP2025138715A/ja active Pending
- 2025-07-21 US US19/275,190 patent/US20260062456A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509776A5 (https=) | ||
| JP7256348B2 (ja) | Ｃｔｌａ４に対する単一ドメイン抗体及びその誘導タンパク質 | |
| KR102501921B1 (ko) | 유도성 결합 단백질 및 사용 방법 | |
| CN109096396B (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
| CN109071627B (zh) | Cd8结合剂 | |
| AU2017204047B2 (en) | High-stability T-cell receptor and preparation method and application thereof | |
| JP2020511144A5 (https=) | ||
| US12421292B2 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| TWI840433B (zh) | 新穎合理設計的蛋白質組合物 | |
| US20190322747A1 (en) | Anti-pd-1 nano-antibody and application thereof | |
| JP2019533449A (ja) | 多量体ｉｌ−１５に基づく分子 | |
| CN114524876B (zh) | 靶向nkg2a的抗体及其用途 | |
| TW201843181A (zh) | 雙特異性重組蛋白及其應用 | |
| KR20200026994A (ko) | 향상된 이중 특이성 폴리펩티드 분자 | |
| JP2019514361A5 (https=) | ||
| KR20180057720A (ko) | 다가 Fv 항체 | |
| AU2016323069A1 (en) | Tunable variant immunoglobulin superfamily domains and engineered cell therapy | |
| JP2022510276A5 (https=) | ||
| AU2014308907A1 (en) | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof | |
| CN116888155A (zh) | Ror1特异性变体抗原结合分子 | |
| TWI825459B (zh) | 一種SIRPα-Fc融合蛋白 | |
| TW201726914A (zh) | 可程式化的通用細胞受器及其使用方法 | |
| JP2024512709A (ja) | プロテアーゼ活性化ポリペプチド | |
| CN116782937A (zh) | 抗pd-1抗体及其用途 | |
| KR20220150222A (ko) | 신규 단백질 |